Connect with us

Technology

Quantiphi Strengthens AI Drug Discovery, Development Collaboration with Transcell Through Strategic Minority Investment

Published

5 months ago

on

MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ — Quantiphi, an award-winning AI-first digital engineering company today announced it has acquired a strategic minority interest in leading stem cell-based biotech innovator Transcell, marking a milestone in AI-supported drug discovery in the life sciences industry.

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the strategic investment aligns with Quantiphi’s decade-plus commitment to solve what matters for enterprises.

“This partnership will help pharma ascertain the safety profile of their novel molecules on human stem cell composed microphysiologies, reduce the need for animal testing and accelerate preclinical decisions and batch release processes for biotherapeutics and vaccines,” Marhok said. “Use of ethical and responsible AI will help with automated bioassay implementation and support scientists in accelerated decision-making processes.”

Transcell Biologics Founder and CEO Dr. Subhadra Dravida said Quantiphi’s investment and involvement are crucial for advancing Transcell’s mission to support animal-free testing strategies as enterprise solutions.

“This collaboration aims to bring adult stem cell technology into practical applications and ultimately improve treatment outcomes,” Dravida said. “Through these synergistic efforts, we are propelling innovation and elevating industry standards for efficient cost and time management.”

Quantiphi Corporate Development Head Dipen Shah said Quantiphi and Transcell are seamlessly integrating AI and biotech to drive advancements in drug discovery and development processes.

“Quantiphi will continue to consider other strategic partnerships and investments across the value chain – from early-stage research to clinical trials – as aligned with our growth and innovation strategy to enhance customer value,” Shah said.

About Quantiphi:

Quantiphi is an award-winning AI-first digital engineering company driven by the desire to reimagine and realize transformational opportunities at the heart of business. Since its inception in 2013, Quantiphi has solved the toughest and most complex business problems by combining deep industry experience, disciplined cloud and data engineering practices, and cutting-edge artificial intelligence research to achieve accelerated and quantifiable business results. Learn more at Quantiphi.com and follow us on Linkedin, X, formerly Twitter and Instagram.

About Transcell

Transcell headquartered in Hyderabad, India is a leading innovation-driven once-in-generation biotech entity developing a portfolio of best-in-class productized offerings by applying their in-house hypothesis-based discovery and development programs. In Transcell’s universe, the applications are of two types: Therapeutics, and Non-Therapeutics while the flagship biosamples repository mediates the compelling journey with the purpose of finding answers for some of the globe’s most urgent complex medical needs.

Media Contact:
H. Mayes
Quantiphi Newsroom
contact.newsroom@quantiphi.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/quantiphi-strengthens-ai-drug-discovery-development-collaboration-with-transcell-through-strategic-minority-investment-302221365.html

SOURCE Quantiphi

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Fangzhou Inc. Honored as an “Outstanding Innovation Firm” by Yangcheng Evening News

Published

24 minutes ago

on

December 27, 2024

By

GUANGZHOU, China, Dec. 27, 2024 /PRNewswire/ — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in Internet healthcare solutions, was honored as an “Outstanding Innovation Firm” at the “Precision Engineering: 2024 Technology Pioneers Gala” held by Yangcheng Evening News on December 13th. Fangzhou garnered recognition for its significant milestones in 2024, including a successful listing on the Main Board of the Hong Kong Stock Exchange, and its role in spearheading the ongoing digital transformation of China’s healthcare sector.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, remarked, “We are thrilled to receive this award from Yangcheng Evening News as an ‘Outstanding Innovation Firm’. Adhering to our corporate mission of ‘Better Health for All’, we will continue to cultivate a bold vision for the future of the Internet healthcare sector.”

2024 has been a significant year in Fangzhou’s development journey. Following its IPO in July 2024, the Company received commendation from the Guangzhou Municipal People’s Government for its contributions in advancing the digital transformation of the healthcare industry and enhancing public health. In October, Fangzhou was featured on the 2024 Guangdong “AI Catalyst” Enterprise Billboard at the 2024 Guangdong-Hong Kong-Macao Greater Bay Area Artificial Intelligence Industry Conference. More recently, the Company launched its ” AI Agent Solution” in November 2024 in partnership with Tencent Healthcare and Baidu Health, providing more efficient access to healthcare information and analysis for both consumers and healthcare professionals.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform. With 45.6 million registered users and 217,000 registered doctors on its platform (as of June 30, 2024), the Company provides tailored medical care and precision medicine for a growing population of chronic disease patients. For more details, visit https://investors.jianke.com.

About Yangcheng Evening News

Yangcheng Evening News, first published in October 1957, was among the first broadly distributed evening newspapers established after the founding of People’s Republic of China. Produced in Guangzhou as the flagship publication of the Yangcheng Evening News Group, the newspaper has built a strong reputation for its critical and independent perspective, delivering engaging news coverage on a variety of topics that resonate with people’s daily lives.

Media Contact

For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com 

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements

View original content to download multimedia:https://www.prnewswire.com/news-releases/fangzhou-inc-honored-as-an-outstanding-innovation-firm-by-yangcheng-evening-news-302339558.html

SOURCE Fangzhou Inc.

Continue Reading

Technology

XCMG Launches Used Equipment Certification to Drive Sustainable Development in Construction Machinery

Published

24 minutes ago

on

December 27, 2024

By

XUZHOU, China, Dec. 27, 2024 /PRNewswire/ — XCMG Machinery (“XCMG”, SHE: 000425) has officially launched the XCMG Certified Used Equipment brand, marking a significant milestone in the development of its circular business. This initiative reflects XCMG’s commitment to addressing industry challenges, promoting green circular economy principles, and accelerating the transition toward sustainable development and carbon neutrality.

In recent years, China’s construction machinery industry has made remarkable strides. Leveraging its deep technological expertise, extensive manufacturing experience, and well-established brand influence, XCMG has established its official certified used equipment brand. This initiative aims to empower industry transformation, enhance the lifecycle value of signature equipment, and offer customers comprehensive quality and service guarantees across the value chain.

At the recent bauma China Exhibition, XCMG and Ritchie Bros. co-hosted a used equipment auction, showcasing over 300 fully inspected and refurbished units from 16 XCMG product categories, including cranes, excavators, mining equipment, compactors, loaders, concrete machinery, and piling equipment. These units were launched on the Ritchie Bros. website, symbolizing a new chapter in the used equipment market.

In line with its vision to become the world’s premier service brand, XCMG also introduced the XCMG TrueCare (“TrueCare”) service brand. TrueCare embodies XCMG’s unrelenting pursuit of integrated solutions, aligning with the Solid to Succeed brand philosophy. The service brand is designed to deliver cutting-edge innovations, stringent quality control, and efficient services, empowering customers to maintain a competitive edge in global markets.

“This initiative will extend the value chain, foster innovation, and elevate XCMG to new heights as a globally recognized brand,” said Liu Jiansen, vice president of XCMG.

The five core missions of XCMG TrueCare are:

Swift: A global service network ensures rapid response to customer needs to minimize downtime.Optimal: Integration of XCMG’s five advanced digital management systems delivers tailored solutions to enhance operational efficiency.Long-term: TCO service models, including extended warranties and certified pre-owned programs, provide full lifecycle care and build lasting customer relationships.Intelligent: Comprehensive smart solutions address customer-specific requirements through the integration of R&D, production, supply, sales, and service.Dedicated: A global call center and a professional team provide 24/7 support, ensuring efficient equipment operation and 100% customer satisfaction.

With these strategic advancements, XCMG is poised to redefine industry standards, driving the adoption of sustainable practices and reinforcing its leadership in the global construction machinery market.

Photo – https://mma.prnewswire.com/media/2588046/XCMG_Launches_Used_Equipment_Certification_Drive_Sustainable_Development_Construction_Machinery.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xcmg-launches-used-equipment-certification-to-drive-sustainable-development-in-construction-machinery-302339562.html

Continue Reading

Technology

Stora Enso Oyj: Notification of Change in Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (25 December 2024)

Published

2 hours ago

on

December 27, 2024

By

STORA ENSO OYJ STOCK EXCHANGE RELEASE 27 December 2024 at 09:00 EET

HELSINKI, Dec. 27, 2024 /PRNewswire/ — Stora Enso Oyj received a notification pursuant to chapter 9, section 5 of the Securities Market Act from BlackRock, Inc on 27 December 2024.

On 25 December 2024, BlackRock’s holding in Stora Enso’s shares decreased below the 5 percent threshold.

% of shares and voting rights (total of 7.A)

% of shares and voting rights through financial instruments (total of 7.B)

Total of both in % (7.A + 7.B)

Resulting situation on the date on which threshold was crossed or reached

4.76% shares

Below 5% voting rights

0.27% shares

Below 5% voting rights

5.04% shares

Below 5% voting rights

Position of previous notification (if applicable)

Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

Below 5% shares

Below 5% voting rights

 

A: Shares and voting rights

Class/type of shares

ISIN code (if possible)

Number of shares and voting rights

% of shares and voting rights

Direct

(SMA 9:5)

Indirect

(SMA 9:6 and 9:7)

Direct

(SMA 9:5)

Indirect

(SMA 9:6 and 9:7)

FI0009005961

37,609,170  shares

Below 5% voting rights

4.76% shares Below 5% voting rights

SUBTOTAL A

37,609,170 shares

Below 5% voting rights

4.76% shares

Below 5% voting rights

B: Financial Instruments according to SMA 9:6a

Type of financial instrument

Expiration date

Exercise/Conversion Period

Physical or cash settlement

Number of shares and voting rights

% of shares and voting rights

American Depositary Receipt (US86210M1062)

N/A

N/A

Physical

596,930 shares

Below 5% voting rights

0.07% shares

Below 5% voting rights

Securites lent

N7A

N/A

Physical

1,036,720 shares

Below 5% voting rights

0.13% shares

Below 5% voting rights

CFD

N/A

N/A

Cash

563,510 shares

Below 5% voting rights

0.07% shares

Below 5% voting rights

SUBTOTAL B

2,197,160 shares

Below 5% voting rights

0.27% shares

Below 5% voting rights

 

Stora Enso has two series of shares. Each A share and every ten R shares carry one vote. Stora Enso has 175,664,079 A shares and 612,955,908 R shares in issue. The Company does not hold its own shares. The total number of Stora Enso shares is 788,619,987 and the total number votes at least 236,959,669.

Investor enquiries:
Anna-Lena Åström
SVP Investor Relations
tel. +46 70 210 7691 

Stora Enso

Part of the global bioeconomy, Stora Enso is a leading provider of renewable products in packaging, biomaterials and wooden construction, and one of the largest private forest owners in the world. We create value with our low-carbon and recyclable fiber-based products, through which we support our customers in meeting the demand for renewable sustainable products. Stora Enso has approximately 20,000 employees and our sales in 2023 were EUR 9.4 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in OTC Markets (OTCQX) in the USA as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors

STORA ENSO OYJ

Investor enquiries:
Anna-Lena Åström
SVP Investor Relations
tel. +46 70 210 7691 

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/stora-enso-oyj/r/stora-enso-oyj–notification-of-change-in-holdings-according-to-chapter-9–section-10-of-the-finnish,c4086606

The following files are available for download:

https://mb.cision.com/Main/13589/4086606/3189711.pdf

STORA ENSO Class R_2024-12-25_Issuer

 

View original content:https://www.prnewswire.com/news-releases/stora-enso-oyj-notification-of-change-in-holdings-according-to-chapter-9-section-10-of-the-finnish-securities-markets-act-25-december-2024-302339535.html

SOURCE Stora Enso Oyj

Continue Reading

Trending